南京医药
(600713)
| 流通市值：64.88亿 | | | 总市值：65.80亿 |
| 流通股本：12.90亿 | | | 总股本：13.08亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 27,822,576,569.95 | 13,843,779,763.6 | 54,963,277,449.95 | 41,135,141,888.47 |
| 营业总成本 | 27,234,806,874.98 | 13,504,978,803.17 | 53,921,722,737.41 | 40,346,990,541.21 |
| 其他经营收益 | | | | |
| 营业利润 | 526,511,321.54 | 284,681,693.04 | 1,160,106,280.91 | 691,410,392.7 |
| 利润总额 | 523,341,758.24 | 281,917,557.9 | 1,157,627,933.72 | 708,545,653.09 |
| 净利润 | 378,501,024.19 | 211,697,444.59 | 832,668,876.52 | 529,756,573.09 |
| 每股收益 | | | | |
| 其他综合收益 | -19,006,250.54 | -13,095,362.19 | -10,643,046.56 | -2,406,240.26 |
| 综合收益总额 | 359,494,773.65 | 198,602,082.4 | 822,025,829.96 | 527,350,332.83 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 33,249,155,558.99 | 32,465,200,997.55 | 28,411,741,404.44 | 31,003,426,359.15 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,080,014,908.83 | 3,039,275,263.67 | 3,018,664,405.93 | 3,041,627,824.3 |
| 资产总计 | 36,329,170,467.82 | 35,504,476,261.22 | 31,430,405,810.37 | 34,045,054,183.45 |
| 流动负债: | | | | |
| 流动负债合计 | 22,900,519,254.91 | 22,430,972,576.41 | 18,520,454,694.33 | 21,445,543,072 |
| 非流动负债: | | | | |
| 非流动负债合计 | 5,124,976,978.48 | 4,610,137,631.04 | 4,657,060,749.56 | 4,641,284,714.85 |
| 负债合计 | 28,025,496,233.39 | 27,041,110,207.45 | 23,177,515,443.89 | 26,086,827,786.85 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,254,907,215.26 | 7,357,581,482.86 | 7,185,054,665.95 | 6,974,165,868.16 |
| 股东权益合计 | 8,303,674,234.43 | 8,463,366,053.77 | 8,252,890,366.48 | 7,958,226,396.6 |
| 负债和股东权益合计 | 36,329,170,467.82 | 35,504,476,261.22 | 31,430,405,810.37 | 34,045,054,183.45 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 23,648,603,036.98 | 10,503,310,948.63 | 55,660,431,363.06 | 37,487,515,677.95 |
| 经营活动现金流出小计 | 28,808,381,959.37 | 15,697,812,024 | 55,568,622,434.11 | 42,464,250,146.2 |
| 经营活动产生的现金流量净额 | -5,159,778,922.39 | -5,194,501,075.37 | 91,808,928.95 | -4,976,734,468.25 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 419,724,626.05 | 219,777,243.86 | 1,524,569,422.27 | 970,217,531.21 |
| 投资活动现金流出小计 | 436,522,279.45 | 257,208,401.67 | 1,720,274,104.16 | 1,426,192,879.45 |
| 投资活动产生的现金流量净额 | -16,797,653.4 | -37,431,157.81 | -195,704,681.89 | -455,975,348.24 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 18,566,246,206.2 | 9,123,845,116.03 | 22,151,533,261.66 | 18,557,106,925.1 |
| 筹资活动现金流出小计 | 13,655,121,733.28 | 5,025,672,719.14 | 22,582,463,807.62 | 14,960,529,499.38 |
| 筹资活动产生的现金流量净额 | 4,911,124,472.92 | 4,098,172,396.89 | -430,930,545.96 | 3,596,577,425.72 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | - |
| 现金及现金等价物净增加额 | -265,452,102.87 | -1,133,759,836.29 | -534,826,298.9 | -1,836,132,390.77 |
| 期末现金及现金等价物余额 | 2,127,858,054.78 | 1,259,550,321.36 | 2,393,310,157.65 | 1,092,004,065.78 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -265,452,102.87 | - | -534,826,298.9 | - |